Summary
EWL Chart
Swiss pharma hub Basel frets over population cap threat
For decades, economic growth in Basel has outpaced that of Switzerland as its globe-straddling pharmaceutical and biotech industries have turned the city on the border with Germany and France into one of the most prosperous in Europe.
Swiss Biotech sector boosted by shift toward private funding, report says
Switzerland's biotech industry shifted toward private financing in 2025 as funding from capital markets remained difficult to obtain and pharmaceutical companies sought out collaborative deals with biotech firms, a report on the sector showed on Tuesday.
EWL: No Energy, Light On Tech, Premium P/E
I maintain a Hold rating on iShares MSCI Switzerland ETF (EWL) due to its premium valuation and mixed technicals. EWL trades at 18.1x earnings with a PEG near 3, limiting its current valuation appeal despite a 14.5% 12-month gain. The ETF is highly liquid, top-heavy in Health Care (notably Novartis and Roche), and lacks significant Tech or Energy exposure.
iShares MSCI Switzerland ETF Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 375 | $20,554 | $23,694.37 | $3,140.37 | 15.28% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 1,093 | $61,925.66 | $68,973.76 | $7,048.1 | 11.38% |
| YA Yinka Akinsola Blue Trust Inc. | 26 | $1,280.97 | $1,638.13 | $357.16 | 27.88% |
| CAL CSM Advisors LLC CSM Advisors LLC | 74,684 | $4.39M | $4.7M | $312,552.54 | 7.12% |
| SAS Stephane Astruc/ Salomon Sebban J. Safra Sarasin Holding AG | 5,768 | $290,516.55 | $363,989.64 | $73,473.09 | 25.29% |
iShares MSCI Switzerland ETF (EWL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has iShares MSCI Switzerland ETF ever had a stock split?
iShares MSCI Switzerland ETF Profile
| ARCA Exchange | US Country |
Overview
The fund in question is an investment vehicle that primarily focuses on replicating the performance of its underlying index, which tracks the large- and mid-cap segments of the Swiss equity market. By allocating at least 80% of its assets in the securities that make up the index and in other investments with similar economic characteristics, the fund aims to offer its investors a focused approach to participating in the Swiss equity space. It operates with a non-diversified strategy, meaning it may concentrate its investments more heavily in fewer issues than a diversified fund would. The underlying index itself is a free float-adjusted, market capitalization-weighted index, underscoring the fund's emphasis on mirroring the market movements and performance of substantial Swiss enterprises.
Products and Services
- Component Securities Investments
The fund invests a substantial portion of its assets directly in the securities that are included in its underlying index. These investments are chosen based on their ability to replicate the economic characteristics and performance of the large- and mid-cap segments of the Swiss equity market. This method allows the fund to closely track the index's performance.
- Investments with Economic Characteristics Identical to Component Securities
In addition to direct investments in component securities of the underlying index, the fund also allocates assets to other investments that have economic characteristics substantially identical to those component securities. This could include derivative contracts or other financial instruments that mimic the performance of the index's securities, providing another layer of strategy aimed at achieving the fund's investment objectives.
